Charlotte S. Walmsley

Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions

Homologous recombination repair deficiency (HRD) occurs in approximately 10% of breast tumors and represents a major targetable vulnerability across multiple cancer types. Impairment of the homologous recombination DNA repair pathway — arising through somatic and germline mutations in homologous recombination repair ge...